All Stories

  1. Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?

    Article • European Respiratory Journal, March 2021, European Respiratory Society (ERS)

    Samy Suissa

  2. Avoiding immortal time bias in observational studies

    Article • European Respiratory Journal, March 2020, European Respiratory Society (ERS)

    Samy Suissa

  3. Inhaled corticosteroid use and the incidence of lung cancer in COPD

    Article • European Respiratory Journal, November 2019, European Respiratory Society (ERS)

    Samy Suissa

  4. Misinterpretation of time-to-first event curves can lead to inappropriate treatment

    Article • European Respiratory Journal, September 2019, European Respiratory Society (ERS)

    Samy Suissa, MD MHA Amnon Philip Ariel

  5. Inhaled corticosteroids and pneumonia mortality in COPD patients

    Article • European Respiratory Journal, September 2019, European Respiratory Society (ERS)

    Samy Suissa

  6. Triple therapy in COPD: only for the right patient

    Article • European Respiratory Journal, April 2019, European Respiratory Society (ERS)

    Samy Suissa, MD MHA Amnon Philip Ariel

  7. Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias?

    Article • European Respiratory Journal, February 2019, European Respiratory Society (ERS)

    Samy Suissa

  8. Triple therapy trials in COPD: Evidence for precision medicine

    Article • European Respiratory Journal, December 2018, European Respiratory Society (ERS)

    Samy Suissa, MD MHA Amnon Philip Ariel

  9. Beta-Blockers in COPD: A Methodological Review of the Observational Studies

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, September 2018, Taylor & Francis

    Samy Suissa

  10. Observational Studies in COPD: Summary of Guidance for Authors

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, September 2018, Taylor & Francis

    Samy Suissa

  11. Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10

    Article • Diabetes Care, May 2018, American Diabetes Association

    Samy Suissa

  12. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies

    Article • European Respiratory Journal, May 2018, European Respiratory Society (ERS)

    Samy Suissa

  13. Food and Drug Administration–mandated Trials of Long-Acting β-Agonist Safety in Asthma. Bang for the Buck?

    Article • American Review of Respiratory Disease, April 2018, American Thoracic Society

    Samy Suissa

  14. Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect

    Article • Diabetes Care, January 2018, American Diabetes Association

    Samy Suissa

  15. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?

    Article • Diabetes Care, December 2017, American Diabetes Association

    Samy Suissa

  16. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

    Article • Diabetes Care, September 2017, American Diabetes Association

    Dr. Antonios Douros, Samy Suissa

  17. Run-in bias in randomised trials: the case of COPD medications

    Article • European Respiratory Journal, June 2017, European Respiratory Society (ERS)

    Samy Suissa

  18. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

    Article • European Respiratory Journal, May 2017, European Respiratory Society (ERS)

    Samy Suissa

  19. Sex, breathing and statistics

    Article • European Respiratory Journal, May 2017, European Respiratory Society (ERS)

    Samy Suissa

  20. The effect of statins on influenza-like illness morbidity and mortality

    Article • Pharmacoepidemiology and Drug Safety, September 2016, Wiley

    Paul Brassard, Samy Suissa

  21. The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations: TABLE 1

    Article • European Respiratory Journal, December 2015, European Respiratory Society (ERS)

    Samy Suissa

  22. Number needed to treat: enigmatic results for exacerbations in COPD

    Article • European Respiratory Journal, December 2015, European Respiratory Society (ERS)

    Samy Suissa

  23. Weaning from inhaled corticosteroids in COPD: the evidence

    Article • European Respiratory Journal, October 2015, European Respiratory Society (ERS)

    Samy Suissa

  24. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes

    Article • European Heart Journal, December 2013, European Society of Cardiology

    Samy Suissa